期刊文献+

糖尿病神经病变患者采用依帕斯他联合舒血宁治疗的效果探究

下载PDF
导出
摘要 探究糖尿病神经病变患者采用依帕斯他联合舒血宁治疗的效果。选择2014年5月~2016年5月107例糖尿病神经病变患者,随机分组,对照组采用依帕斯他口服治疗,观察组采用依帕斯他联合舒血宁进行治疗,比较两组患者的临床疗效、肝肾功能指标、血糖血脂水平、神经传导速度。结果(1)观察组临床有效率为96%,对照组临床有效率为61.40%,观察组明显高于对照组,组间对比差异显著(P<0.05)。(2)观察组和对照组治疗前后谷丙转氨酶、尿素氮、肌酐水平无明显差异,不具有统计学意义(P>0.05)。组间对比无明显差异(P>0.05)。(3)两组患者FPG、P2hPG、HbA1c、TC、TG、LDL-C、BMI指数明显比治疗前降低,HDL-C明显上升,数据比较差异显著(P<0.05);观察组FPG、P2hPG、HbA1c、TC、TG、LDL-C、BMI明显低于对照组,HDL-C明显更高,数据比较差异显著(P<0.05)。(4)和对照组对比,观察组治疗后后腓感觉神经、正中感觉神经、腓运动神经、正中运动神经传导速度明显更快,数据比较差异显著(P<0.05)。糖尿病神经病变患者采用依帕斯他联合舒血宁治疗的效果显著,能够有效地改善患者的神经功能,值得推广。
出处 《现代诊断与治疗》 CAS 2017年第11期2011-2012,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献5

二级参考文献60

  • 1Pop-Busui R, Low PA, Waberski BH, et al. Effects of prior inten- sive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC) [J]. Circulation, 2009,119(22):2886-2893. 被引量:1
  • 2Bouhorl AJ,Vinik AI, Arezzo JC,et al. Diabetic neuropathies: a state- ment by the American Diabetes Association[J].Diabetes Care, 2005, 28(4):956-962. 被引量:1
  • 3Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy[J]. Curr Diab Rep , 2009, 9(6):423-431. 被引量:1
  • 4Martin CL,Waberski BH,Pop-Busui R,et al. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes results from the DCCT/EDIC study [J]. Diabetes Care, 2010,33(12) : 2635-2641. 被引量:1
  • 5Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the di- agnosis and staging of diabetic neuropathy [J].Diabetes Care ,1994, 17(11): 1281-1289. 被引量:1
  • 6American Diabetes Association. Standards of medical care in diabe- tes - 2008 edition[J]. Diabetes Care, 2008,31(Suppl I):S12-S54. 被引量:1
  • 7Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac au- tonomic dysfunction on mortality risk in the Action to Control Car- diovascular Risk in Diabetes (ACCORD) trial [J]. Diabetes Care, 2010,33(7): 1578-1584. 被引量:1
  • 8Pop-Busui R, Lu J, Lopes N, et al.Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort [J]. J Peripher Nerv Syst ,2009,14(1): 1-13. 被引量:1
  • 9Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy [J]. Clin Neurol Neuro surg,2006, 108(5):477-481. 被引量:1
  • 10Herman WH,Pop-Vusui R,Braffett BH,et al.Use of the Michigan Neuropathy Screening Instruments as a measure of distal symmetri- cal peripheral neuropathy in Type 1 diabetes:resuhs from the Diabe- tes Control and Complications Trial/Epidemiology of Diabetes Inter- ventions and Complications [J].Diabetic Med,2012,29(7):937-944. 被引量:1

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部